The most-researched healing peptide in existence. For lifters, BPC-157 is the go-to for tendon and joint repair, post-surgical recovery, and gut healing from oral PED use. It works by upregulating growth factor expression (VEGF, EGF) and promoting angiogenesis at injury sites.
In animal models, BPC-157 accelerated tendon-to-bone healing by 72% compared to controls over a 14-day observation period.
Chang et al., Journal of Orthopaedic Research, 2011
| Molecular Formula | C62H98N16O22 |
| Structure | 15-amino acid pentadecapeptide |
| Half-Life | Stable in gastric juice; ~4 hours estimated |
| Administration | Subcutaneous injection, oral (capsule) |
| Legal Status | Category 1 |
| Power Rating | 4/5 |
BPC-157 activates the FAK-paxillin pathway, promoting tendon fibroblast migration and outgrowth. It upregulates vascular endothelial growth factor (VEGF) receptor expression, accelerating angiogenesis at injury sites. In the gut, it interacts with the dopaminergic and nitric oxide (NO) systems to protect mucosal integrity and counteract NSAID-induced damage.
BPC-157 has been studied extensively in over 100 published papers, primarily in rodent models. Research demonstrates significant effects on tendon repair, muscle healing, gut mucosal protection, liver regeneration, and nerve recovery. A 2025 pilot study confirmed IV BPC-157 safety in humans at doses up to 20mg, marking the first formal human safety data. The peptide shows cytoprotective properties across multiple organ systems and has demonstrated the ability to counteract damage from NSAIDs, alcohol, and various toxins.
BPC-157 is generally well-tolerated in research settings. Reported side effects are rare and typically mild, including injection site reactions (redness, minor swelling), occasional nausea at higher doses, and dizziness. No significant adverse events have been reported in published literature. The 2025 human pilot study reported no serious adverse events at any dose level tested.
BPC-157 is classified as Category 1 (cleared) under the 2024 HHS peptide reclassification framework. It is available for compounding by 503A pharmacies with a valid prescription, and as a research chemical from specialized vendors. It is not FDA-approved as a pharmaceutical drug.
All vendors listed sell products labeled strictly for research purposes only.